Therapeutic Focus Areas
We concentrate on therapeutic categories with strong clinical precedence, established regulatory pathways, and significant public health impact across three core areas.
Strategic Market Positioning
Our focus areas represent over €180 billion in combined global market value, with strong growth trajectories and clear opportunities for generic and biosimilar development.
Market Growth
8.2%
Average CAGR across focus areas
Patient Impact
500M+
Patients served globally
Pipeline Depth
25+
Products under evaluation
Oncology
Late-stage generics & biosimilarsWe focus on established oncology therapies with proven clinical efficacy and clear regulatory pathways. Our approach emphasizes late-stage generic development and biosimilar opportunities in solid tumors and hematological malignancies.
Key Areas:
- • Targeted therapy generics (kinase inhibitors)
- • Monoclonal antibody biosimilars
- • Supportive care medications
- • Combination therapy formulations
Development Focus
Therapeutic Classes
- • GLP-1 analogs
- • Insulin biosimilars
- • SGLT-2 inhibitors
- • ACE inhibitors
- • ARB combinations
- • Calcium blockers
Cardio-metabolic
Chronic disease managementAddressing the global burden of cardiovascular disease and diabetes through accessible generic formulations. We focus on established therapies with strong safety profiles and proven long-term outcomes in chronic disease management.
Strategic Priorities:
- • Fixed-dose combination products
- • Extended-release formulations
- • Biosimilar insulin products
- • Novel delivery systems
Immunology
Biosimilars in established classesEvaluation and development of biosimilars in proven immunological therapies. Our focus is on well-characterized biological products with established clinical use patterns and clear biosimilar development pathways.
Target Areas:
- • TNF-alpha inhibitor biosimilars
- • Interleukin pathway modulators
- • Autoimmune disease treatments
- • Inflammatory bowel disease therapies
Development Timeline
Partnership Opportunities
We maintain a dynamic evaluation pipeline and welcome discussions on co-development, in-licensing, and strategic partnerships across all therapeutic areas.
Discuss opportunitiesView partnership modelsThis website provides non-promotional corporate information and does not offer medical advice or product availability.